MSF Access Campaign 253d ago

Brussels, 14 October 2025: Although tuberculosis (TB) is both preventable and curable, people with TB across Europe continue to face unnecessary suffering due to limited access to effective treatment and prevention medicines. While low and middle-income countries having high burden of TB have taken measures to improve access to new and existing medicines and other medical tools, inadequate access to new and existing medicines and slow adoption of updated treatment guidance by the World Health Organization remain a major challenge in many countries in the European Union (EU) and European Economic Area (EEA).    Drawing on findings from MSF’s recent Technical Brief (https://msfaccess.org/bridging-gap-securing-access-essential-tb-medicines-eu-and-eea) , MSF hosted a panel discussion to highlight key barriers to access and explore the important role that different actors can play at both national and regional level in improving the availability and affordability of TB medicines.